Indicator number | Indicator and sets of indicators | Eligible encounters (N) | Compliant encounters (N) | Compliance* (%) | 95% confidence limits† (%) |
---|---|---|---|---|---|
45–48 | Patients undergoing certain orthopaedic procedures or care received appropriate pharmacological anticoagulant therapy | 55 | 34 | 62 | 48–75 |
45 | Patients who had a hip arthroplasty have received anticoagulant therapy for up to 35 days‡ | 22 | 12 | Insufficient data to report | |
46 | Patients who had hip fracture surgery have received anticoagulant therapies for up to 35 days§ | 2 | 2 | Insufficient data to report | |
47 | Patients who had a knee arthroplasty received anticoagulant therapies for up to 28 days¶ | 24 | 16 | Insufficient data to report | |
48 | Patients who had a lower limb fracture received anticoagulant therapies for at least 5 days or until fully mobile§ | 7 | 4 | Insufficient data to report | |
62, 68–70, 73–75 | Patients undergoing certain orthopaedic procedures or care received appropriate mechanical anticoagulant therapy | 104 | 49 | 47 | 37–57 |
62 | Patients having a total hip replacement have been prescribed graduation compression stockings | 20 | 19 | Insufficient data to report | |
68 | Patients having a total hip replacement have been prescribed an intermittent pneumatic compression device | 18 | 11 | Insufficient data to report | |
69 | Patients having hip fracture surgery have been prescribed an intermittent pneumatic compression device | 3 | 1 | Insufficient data to report | |
70 | Patients having a total knee replacement have been prescribed an intermittent pneumatic compression device | 21 | 15 | Insufficient data to report | |
73 | Patients having a total hip replacement have been prescribed a foot pump | 18 | 1 | Insufficient data to report | |
74 | Patients having a total knee replacement have been prescribed a foot pump | 22 | 2 | Insufficient data to report | |
75 | Patients having hip fracture surgery have been prescribed a foot pump | 2 | 0 | Insufficient data to report | |
49–54 | Patients undergoing non-orthopaedic surgical procedures (general, gynaecological, abdominal, cardiac, thoracic or vascular, trauma or spinal surgery) or who had cancer and underwent surgery received appropriate pharmacological anticoagulant therapy | 226 | 76 | 34 | 27–41 |
49 | Patients who had a general surgical procedure received anticoagulant therapies (unless contraindicated) until hospital discharge or fully mobile** | 55 | 19 | 35 | 22–49 |
50 | Patients who had gynaecological surgery received anticoagulant therapies (unless contraindicated) until hospital discharge or fully mobile** | 26 | 5 | Insufficient data to report | |
51 | Patients who had abdominal surgery received anticoagulant therapies (unless contraindicated) until hospital discharge or fully mobile** | 61 | 29 | 48 | 18–78 |
52 | Patients who had cardiac, thoracic or vascular surgery received anticoagulant therapies (unless contraindicated) until hospital discharge or fully mobile** | 31 | 12 | 39 | 16–66 |
53 | Patients who had trauma or spinal surgery received anticoagulant therapies started after primary haemostasis was established (unless contraindicated) until hospital discharge or fully mobile** | 18 | 0 | Insufficient data to report | |
54 | Patients who have cancer that underwent surgery received one of the following anticoagulant therapies (unless contraindicated) until hospital discharge or fully mobile** | 35 | 11 | 31 | 5–74 |
63–67, 71–72 | Patients undergoing non-orthopaedic surgical procedures received appropriate mechanical anticoagulant therapy | 294 | 176 | 60 | 52–67 |
63 | Patients having general surgery have been prescribed graduated compression stockings | 72 | 63 | 88 | 78–94 |
64 | Patients having gynaecological surgery have been prescribed graduation compression stockings | 28 | 21 | Insufficient data to report | |
65 | Patients having abdominal surgery have been prescribed graduation compression stockings | 66 | 48 | 73 | 46–91 |
66 | Patients having cardiac, thoracic or vascular surgery have been prescribed graduation compression stockings | 52 | 17 | 33 | 2–85 |
67 | Patients having neurosurgery have been prescribed graduation compression stockings | 13 | 11 | Insufficient data to report | |
71 | Patients having cardiac, thoracic or vascular surgery have been prescribed an intermittent pneumatic compression device | 50 | 7 | 14 | 2–41 |
72 | Patients having neurosurgery have been prescribed an intermittent pneumatic compression devices | 13 | 9 | Insufficient data to report | |
55–61 | Medical patients admitted to hospital with certain conditions received appropriate pharmacological anticoagulant therapy | 167 | 77 | 46 | 36–57 |
55 | Medical patients admitted to hospital with ischaemic stroke received anticoagulant therapies until resolution of the acute medical illness or until hospital discharge†† | 5 | 1 | Insufficient data to report | |
56 | Medical patients admitted to hospital with myocardial infarct (where full anticoagulant is not in use) received anticoagulant therapies until resolution of the acute medical illness or until hospital discharge†† | 15 | 6 | Insufficient data to report | |
57 | General medical patients admitted to hospital assessed as being at risk of VTE received anticoagulant therapies until resolution of the acute medical illness or until hospital discharge†† | 84 | 43 | 51 | 40–62 |
58 | Medical patients admitted to hospital with active cancer received anticoagulant therapies until resolution of the acute medical illness or until hospital discharge†† | 23 | 8 | Insufficient data to report | |
59 | Medical patients admitted to hospital with decompensated cardiac failure received anticoagulant therapies until resolution of the acute medical illness or until hospital discharge†† | 7 | 3 | Insufficient data to report | |
60 | Medical patients admitted to hospital with acute on chronic lung disease received anticoagulant therapies until resolution of the acute medical illness or until hospital discharge†† | 31 | 15 | 48 | 30–67 |
61 | Medical patients admitted to hospital with acute on chronic inflammatory disease received anticoagulant therapies until resolution of the acute medical illness or until hospital discharge†† | 2 | 1 | Insufficient data to report | |
76–80 | Patients with suspected PE/DVT were managed with appropriate investigations, or had anticoagulant therapy started as soon as clinically suspected; or if PE/DVT confirmed, were managed appropriately | 89 | 57 | 64 | 51–76 |
76 | Patients with a suspected DVT had a venous duplex ultrasound performed | 12 | 10 | Insufficient data to report | |
77 | Patients with a suspected PE had investigations performed‡‡ | 21 | 17 | Insufficient data to report | |
78 | Patients with a suspected DVT or PE where ultrasound was delayed, had anticoagulant therapy started (unless contraindicated) as soon as clinically suspected | 10 | 8 | Insufficient data to report | |
79 | Patients with a confirmed DVT/PE received anticoagulant therapies§§ | 6 | 3 | Insufficient data to report | |
80 | Patients who were administered heparin therapy had it continued until the INR had been therapeutic for 48 h (INR range 2.0–3.0) | 40 | 19 | 48 | 26–70 |
Patients discharged on anticoagulant therapy have an appropriate documented care plan including details on the intended duration of treatment AND a review date¶¶ | 70 | 32 | 46 | 31–61 | |
43 | Patients who are discharged on anticoagulant therapy have a documented care plan that includes details on the intended duration of treatment | 73 | 43 | 59 | 46–71 |
44 | Patients who are discharged on anticoagulant therapy have a documented care plan that includes a review date | 70 | 35 | 50 | 29–71 |
Bold typeface indicates the aggregated indicators.
*Percentage compliance calculated as the number of compliant encounters/number of eligible encounters ×100.
†Compliance and per cent of compliance were not calculated for <30 encounters.
‡Enoxaparin 40 mg/day; dalteparin 5000 U/day; LDUH 5000 u three times a day; fondiparinux 2.5 mg/day (started 6–8 h postoperatively); rivaroxaban (orally); dabigatran (orally).
§Enoxaparin 40 mg/day; dalteparin 5000 U/day; LDUH 5000 u three times a day; fondiparinux 2.5 mg/day (started 6–8 h postoperativey).
¶Enoxaparin 40 mg/day; dalteparin 5000 U/day; LDUH 5000 u three times a day; fondiparinux 2.5 mg/day (started 6–8 h postoperatively); rivaroxaban(orally); dabigatran (orally).
**Enoxaparin 20 mg/day; dalteparin 2500 U/day.
††Enoxaparin 40 mg/day; dalteparin 5000 U/day; LDUH 5000 U two times or three times a day; assumed implicit and explicit risk assessments included.
‡‡One of: ventilation perfusion scan; CT angiography; pulmonary angiography.
§§Heparin administered together with warfarin for at least 5 days; unfractionated heparin intravenous (APTT) or subcutaneous (dose/kg); LMWH subcutaneously at least once daily.
¶¶Compliance for this aggregated indicator was both indicators 43 and 44 were compliant for a participant in an episode of hospitalisation. In other aggregated indicators, compliance was measured by adding each individual encounter as each episode of hospitalisation was an independent event.
APTT, activated partial thromboplastin time; DVT, deep venous thrombosis; INR, international normalised ratio; LDUH, low-dose unfractionated heparin; LMWH, low molecular weight heparin; PE, pulmonary embolism; VTE, venous thromboembolism.